No Data
No Data
Ningbo Menovo Pharmaceutical (603538.SH) is actively seeking partners to invest in and construct high-end formulation projects.
On July 25, Glodon News reported that Ningbo Menovo Pharmaceutical (603538.SH) stated on the interactive platform that due to changes in the market and industry policies, the selected preparations for the "high-end preparation project" are no longer suitable for continued investment due to the rapid product upgrades, low bid prices for centralized procurement, intense market competition, and saturation. The company has decided to re-evaluate the specific products to be invested in and temporarily suspend the implementation of the "high-end preparation project." The company is currently actively seeking partners to invest in and develop high-end preparations. The company has conducted more comprehensive and in-depth research on preparation products, and intends to combine the latest industry developments to improve the company's
Menovar (603538.SH): The subsidiary obtained a drug registration certificate for propofovir fumarate tablets
Ningbo Menovo Pharmaceutical, a wholly-owned subsidiary of Menovo Pharmaceuticals (603538.SH), recently received the drug registration certificate for propofol disodium fosphenytoin/telbivudine tablets issued by the National Medical Products Administration. The drug is indicated for the treatment of chronic hepatitis B in adults and adolescents (aged 12 and above, weighing at least 35 kg).
Ningbo Menovo Pharmaceutical (603538.SH) 2023 equity distribution: distributing 0.02 yuan per share.
Ningbo Menovo Pharmaceutical (603538.SH) announced that the company's annual equity distribution will be implemented in 2023: before the implementation of the plan...
Ningbo Menovo Pharmaceutical (603538.SH): Received a government subsidy of 2.5973 million yuan.
Ningbo Menovo Pharmaceutical (603538.SH) announced that from May 1, 2024 to the date of this announcement, the company and its subsidiaries have received a total of RMB 2.5973 million in government grants related to revenue, accounting for 22.42% of the audited net income attributable to the listed company in the latest period.
Menovo Pharmaceutical Unit Gets Registration Certificate for Glucosamine Sulfate Capsules
Ningbo Menovo Pharmaceutical (603538.SH): Wholly-owned subsidiary obtained pharmaceutical registration certificate for ammonium sulfate glucosamine capsules.
Ningbo Menovo Pharmaceutical, a wholly-owned subsidiary of Menovo Pharmaceutical (603538.SH), announced on June 25th that it has recently received the Drug Registration Certificate for Glucosamine Sulfate Capsules from the National Medical Products Administration. The drug is used for the treatment of primary and secondary osteoarthritis.
No Data